Meitav Investment House Ltd. Sells 16,067 Shares of Moderna, Inc. $MRNA

Meitav Investment House Ltd. trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 37.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,143 shares of the company’s stock after selling 16,067 shares during the period. Meitav Investment House Ltd.’s holdings in Moderna were worth $1,379,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRNA. Vanguard Group Inc. grew its holdings in shares of Moderna by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock valued at $1,226,335,000 after purchasing an additional 399,487 shares in the last quarter. Capital World Investors purchased a new stake in Moderna during the fourth quarter valued at $378,299,000. Invesco Ltd. lifted its position in Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after purchasing an additional 1,115,131 shares during the last quarter. Theleme Partners LLP lifted its position in Moderna by 2.5% during the third quarter. Theleme Partners LLP now owns 8,068,810 shares of the company’s stock valued at $208,417,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Moderna by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock worth $136,290,000 after buying an additional 309,126 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Trading Down 2.5%

Shares of MRNA opened at $79.77 on Wednesday. The company’s fifty day simple moving average is $54.66 and its 200-day simple moving average is $48.93. The company has a market cap of $31.65 billion, a P/E ratio of -9.79 and a beta of 0.94. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $85.60.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to analysts’ expectations of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.Moderna’s revenue for the quarter was up 260.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.52) earnings per share. As a group, analysts expect that Moderna, Inc. will post -6.51 EPS for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research reports. Morgan Stanley set a $33.00 target price on shares of Moderna in a report on Friday, May 1st. Barclays increased their price target on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. The Goldman Sachs Group boosted their price objective on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Finally, Piper Sandler upped their price objective on Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, June 26th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $37.87.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Abbas Hussain sold 5,682 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the transaction, the director directly owned 12,066 shares in the company, valued at approximately $562,637.58. This represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,088 shares of company stock worth $6,193,713 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.